Phase II Trial of Trimetrexate in Patients with Stage III and IV Non-Small-Cell Lung Cancer

Authors:
  • RDRobert W. Dʼacquisto
    Robert W. Dʼacquisto
  • RGRichard J. Gralla
    Richard J. Gralla
  • MBM Thomasine Burke
    M Thomasine Burke
  • LMLinda D. Marks
    Linda D. Marks
  • MFMichael P. Fanucchi
    Michael P. Fanucchi
  • RHRobert T. Heelan
    Robert T. Heelan

Abstract
Trimetrexate is a nonclassical antifolate with greater preclinical antitumor activity than methotrexate. Fourteen patients with stage III or IV non-small-cell lung cancer who had not previously received chemotherapy were given trimetrexate (12 mg/m2 intravenously daily for 5 days) every 3 weeks. No major objective responses were observed (95% confidence limits: 0-20%). Ten of the 14 patients had grade 2 or greater toxicity, with 50% experiencing grade 2 or greater leukopenia and/or thrombocytopenia. Nausea, vomiting, rash, mucositis, diarrhea, and serum glutamic-oxaloacetic transaminase (SGOT) elevations were also seen. At the dosage and schedule of trimetrexate used, no responses occurred in this population of patients with non-small-cell lung cancer. With the low response rate and the observed degree of myelosuppression, trimetrexate appears to have limited utility in this disease.

This publication has 12 references indexed in Scilit: